SG10201910742VA - Naphthyridine compounds as jak kinase inhibitors - Google Patents

Naphthyridine compounds as jak kinase inhibitors

Info

Publication number: SG10201910742VA
Authority: SG; Singapore
Prior art keywords: kinase inhibitors; jak kinase; naphthyridine compounds; naphthyridine; compounds
Prior art date: 2015-05-28

Application number

SG10201910742VA

Inventor

Ryan Hudson

Jennifer Kozak

Paul R Fatheree

Dante D Podesto

Gary E L Brandt

Melissa Fleury

Anne-Marie Beausoleil

Xiaojun Huang

Venkat R Thalladi

Original Assignee

Theravance Biopharma R&D Ip Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-28

Filing date

2016-05-26

Publication date

2020-01-30

2016-05-26 Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc

2020-01-30 Publication of SG10201910742VA publication Critical patent/SG10201910742VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201910742VA 2015-05-28 2016-05-26 Naphthyridine compounds as jak kinase inhibitors SG10201910742VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562167694P	2015-05-28	2015-05-28
US201662312273P	2016-03-23	2016-03-23

Publications (1)

Publication Number	Publication Date
SG10201910742VA true SG10201910742VA (en)	2020-01-30

Family

ID=56118022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201910742VA SG10201910742VA (en)	2015-05-28	2016-05-26	Naphthyridine compounds as jak kinase inhibitors

Country Status (31)

Country	Link
US (6)	US9725470B2 (en)
EP (2)	EP3303348B1 (en)
JP (4)	JP6692836B2 (en)
KR (1)	KR20180011272A (en)
CN (2)	CN111362975B (en)
AU (2)	AU2016267141B2 (en)
BR (1)	BR112017025542A2 (en)
CA (1)	CA2983453A1 (en)
CL (1)	CL2017002994A1 (en)
CO (1)	CO2017012267A2 (en)
CY (1)	CY1122279T1 (en)
DK (1)	DK3303348T3 (en)
EA (1)	EA032953B1 (en)
ES (2)	ES2753159T3 (en)
HU (1)	HUE046130T2 (en)
IL (3)	IL255358B (en)
LT (1)	LT3303348T (en)
ME (1)	ME03610B (en)
MX (2)	MX378963B (en)
PH (1)	PH12017502050B1 (en)
PL (1)	PL3303348T3 (en)
PT (1)	PT3303348T (en)
RS (1)	RS59522B1 (en)
SA (1)	SA517390337B1 (en)
SG (1)	SG10201910742VA (en)
SI (1)	SI3303348T1 (en)
SM (1)	SMT201900587T1 (en)
TW (2)	TWI746178B (en)
UA (1)	UA121138C2 (en)
WO (1)	WO2016191524A1 (en)
ZA (1)	ZA201707326B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3303348T3 (en)	2015-05-28	2019-11-11	Theravance Biopharma R&D Ip Llc	Naphthyridine compounds as JAK kinase inhibitors
EP3712152B1 (en)	2015-11-03	2021-01-13	Topivert Pharma Limited	4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077288A1 (en)	2015-11-03	2017-05-11	Topivert Pharma Limited	4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
AU2017258186B2 (en) *	2016-04-28	2020-09-17	Theravance Biopharma R&D Ip, Llc	Pyrimidine compounds as JAK kinase inhibitors
ES2922379T3 (en)	2016-12-16	2022-09-14	Janssen Pharmaceutica Nv	Imidazo[4,5,D]pyrrolo[2,3,B]pyridine compounds as inhibitors of Janus kinases
JOP20190144A1 (en)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	Imidazopyrrolopyridine as inhibitors of the jak family of kinases
AU2018354370B2 (en) *	2017-10-27	2023-04-27	Theravance Biopharma R&D Ip, Llc	Pyrimidine compound as JAK kinase inhibitor
TW202016110A (en)	2018-06-15	2020-05-01	比利時商健生藥品公司	Small molecule inhibitors of the JAK kinase family
US12171764B2 (en)	2018-06-20	2024-12-24	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
CN111601804B (en) *	2018-11-27	2024-06-04	江苏豪森药业集团有限公司	Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof
MX2021006283A (en)	2018-11-30	2021-10-22	Jiangsu Hansoh Pharmaceutical Group Co Ltd	Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof.
KR20210142154A (en)	2019-03-21	2021-11-24	옹쎄오	DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
AR118768A1 (en)	2019-04-24	2021-10-27	Theravance Biopharma R&D Ip Llc	PYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES
HRP20241053T1 (en) *	2019-04-24	2024-11-08	Theravance Biopharma R&D Ip, Llc	STRONG PYRIMIDINE INHIBITORS, INTENDED FOR THE TREATMENT OF SKIN DISEASES
CN114761006A (en)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN113717202B (en) *	2020-05-25	2025-10-17	上海翰森生物医药科技有限公司	Free alkali crystal form of heteroaromatic derivative and preparation method thereof
TW202144366A (en) *	2020-05-25	2021-12-01	大陸商上海翰森生物醫藥科技有限公司	Salt and crystal form of heteroaromatic derivatives and preparation method thereof
WO2022076714A1 (en)	2020-10-09	2022-04-14	Janssen Biotech, Inc.	Solid forms of a pan-jak inhibitor
US11795180B2 (en) *	2020-10-09	2023-10-24	Theravance Biopharma R&D Ip, Llc	Formulation of a pan-JAK inhibitor
EP4225754A1 (en) *	2020-10-09	2023-08-16	Theravance Biopharma R&D IP, LLC	Processes for preparing a pan-jak inhibitor and related intermediate compounds
WO2022076717A1 (en)	2020-10-09	2022-04-14	Janssen Biotech, Inc.	Solvate forms of a pan-jak inhibitor
EP4284801A4 (en) *	2021-02-01	2025-04-23	Janssen Biotech, Inc.	Small molecule inhibitors of salt-inducible kinases
JP2024509587A (en)	2021-03-11	2024-03-04	ヤンセンファーマシューティカエヌ．ベー．	LORPUCITINIB for use in treating JAK-mediated disorders
WO2022241188A1 (en)	2021-05-14	2022-11-17	Theravance Biopharma R&D Ip, Llc	Enantioselective synthesis of aminotropane compound
WO2023011359A1 (en) *	2021-08-05	2023-02-09	南京明德新药研发有限公司	Bridged ring compound and use thereof
WO2023102800A1 (en)	2021-12-09	2023-06-15	Theravance Biopharma R&D Ip, Llc	Synthesis of 5, 7-dichloro-1, 6-naphthyridine
WO2023202706A1 (en) *	2022-04-21	2023-10-26	南京明德新药研发有限公司	Salt form and crystal form of selenium heterocyclic compound and application thereof
WO2024022444A1 (en)	2022-07-27	2024-02-01	江苏恒瑞医药股份有限公司	Fused ring compound, preparation method therefor and medicinal application thereof
AU2024282654A1 (en)	2023-05-30	2025-12-04	Paragon Therapeutics, Inc.	Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613776B2 (en)	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
ATE354573T1 (en)	2000-12-21	2007-03-15	Vertex Pharma	ßPYRAZOLE COMPOUNDS THAT ARE SUITABLE AS PROTEIN KINASE INHIBITORS
EP1595881A1 (en) *	2004-05-12	2005-11-16	Pfizer Limited	Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
CA2588220A1 (en) *	2004-12-23	2006-06-29	Pfizer Products Inc.	Heteroaromatic derivatives useful as anticancer agents
US7572809B2 (en) *	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
AU2008234822A1 (en) *	2007-04-02	2008-10-09	Palau Pharma, S. A.	Pyrrolopyrimidine derivatives as JAK3 inhibitors
WO2010002472A1 (en) *	2008-07-02	2010-01-07	Ambit Biosciences Corporation	Jak kinase modulating compounds and methods of use thereof
CA2732087A1 (en) *	2008-08-05	2010-02-11	Boehringer Ingelheim International Gmbh	Substituted naphthyridines and their use as medicaments
RU2011116928A (en)	2008-09-30	2012-11-20	Астразенека Аб (Se)	HETEROCYCLIC INHIBITORS JAK KINASES
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
WO2012022045A1 (en) *	2010-08-20	2012-02-23	Hutchison Medipharma Limited	Pyrrolopyrimidine compounds and uses thereof
EP2527344A1 (en) *	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CN105367555B (en)	2014-08-07	2019-06-25	广东东阳光药业有限公司	Substituted heteroaryl compound and combinations thereof and purposes
DK3303348T3 (en)	2015-05-28	2019-11-11	Theravance Biopharma R&D Ip Llc	Naphthyridine compounds as JAK kinase inhibitors
AU2017258186B2 (en)	2016-04-28	2020-09-17	Theravance Biopharma R&D Ip, Llc	Pyrimidine compounds as JAK kinase inhibitors

2016
- 2016-05-26 DK DK16728495T patent/DK3303348T3/en active
- 2016-05-26 PT PT167284959T patent/PT3303348T/en unknown
- 2016-05-26 RS RS20191390A patent/RS59522B1/en unknown
- 2016-05-26 KR KR1020177037794A patent/KR20180011272A/en not_active Ceased
- 2016-05-26 JP JP2017561259A patent/JP6692836B2/en active Active
- 2016-05-26 EP EP16728495.9A patent/EP3303348B1/en active Active
- 2016-05-26 UA UAA201712873A patent/UA121138C2/en unknown
- 2016-05-26 EP EP19182836.7A patent/EP3569604B1/en active Active
- 2016-05-26 SG SG10201910742VA patent/SG10201910742VA/en unknown
- 2016-05-26 SI SI201630490T patent/SI3303348T1/en unknown
- 2016-05-26 MX MX2017015211A patent/MX378963B/en unknown
- 2016-05-26 US US15/165,126 patent/US9725470B2/en active Active
- 2016-05-26 LT LT16728495T patent/LT3303348T/en unknown
- 2016-05-26 ME MEP-2019-289A patent/ME03610B/en unknown
- 2016-05-26 SM SM20190587T patent/SMT201900587T1/en unknown
- 2016-05-26 BR BR112017025542-1A patent/BR112017025542A2/en active Search and Examination
- 2016-05-26 HU HUE16728495A patent/HUE046130T2/en unknown
- 2016-05-26 CN CN202010325911.7A patent/CN111362975B/en active Active
- 2016-05-26 CN CN201680029912.9A patent/CN107667108B/en active Active
- 2016-05-26 WO PCT/US2016/034243 patent/WO2016191524A1/en not_active Ceased
- 2016-05-26 MX MX2020011774A patent/MX383074B/en unknown
- 2016-05-26 CA CA2983453A patent/CA2983453A1/en not_active Abandoned
- 2016-05-26 PL PL16728495T patent/PL3303348T3/en unknown
- 2016-05-26 EA EA201792619A patent/EA032953B1/en unknown
- 2016-05-26 ES ES16728495T patent/ES2753159T3/en active Active
- 2016-05-26 AU AU2016267141A patent/AU2016267141B2/en not_active Ceased
- 2016-05-26 ES ES19182836T patent/ES2924698T3/en active Active
- 2016-05-27 TW TW109132390A patent/TWI746178B/en not_active IP Right Cessation
- 2016-05-27 TW TW105116751A patent/TWI704152B/en not_active IP Right Cessation
2017
- 2017-06-23 US US15/631,220 patent/US10072026B2/en active Active
- 2017-10-27 ZA ZA2017/07326A patent/ZA201707326B/en unknown
- 2017-10-31 IL IL255358A patent/IL255358B/en active IP Right Grant
- 2017-11-09 PH PH12017502050A patent/PH12017502050B1/en unknown
- 2017-11-14 SA SA517390337A patent/SA517390337B1/en unknown
- 2017-11-27 CL CL2017002994A patent/CL2017002994A1/en unknown
- 2017-11-29 CO CONC2017/0012267A patent/CO2017012267A2/en unknown
2018
- 2018-08-06 US US16/055,386 patent/US10494382B2/en active Active
2019
- 2019-10-11 US US16/599,434 patent/US10947254B2/en active Active
- 2019-11-06 CY CY20191101165T patent/CY1122279T1/en unknown
2020
- 2020-01-15 IL IL272057A patent/IL272057B/en active IP Right Grant
- 2020-03-19 JP JP2020049467A patent/JP6850922B2/en active Active
- 2020-03-27 AU AU2020202181A patent/AU2020202181B2/en not_active Ceased
- 2020-08-12 IL IL276677A patent/IL276677B/en active IP Right Grant
- 2020-09-16 JP JP2020155460A patent/JP6942853B2/en active Active
2021
- 2021-02-10 US US17/248,832 patent/US11780852B2/en active Active
- 2021-03-22 JP JP2021047526A patent/JP2021098757A/en not_active Withdrawn
2023
- 2023-09-05 US US18/242,434 patent/US12358931B2/en active Active

Also Published As

Publication number	Publication date
EP3569604B1 (en)	2022-07-06
EP3569604A1 (en)	2019-11-20
US20240132520A1 (en)	2024-04-25
JP6692836B2 (en)	2020-05-13
JP2020111593A (en)	2020-07-27
LT3303348T (en)	2019-11-25
IL255358B (en)	2020-01-30
US20210179637A1 (en)	2021-06-17
US11780852B2 (en)	2023-10-10
MX378963B (en)	2025-03-10
SI3303348T1 (en)	2019-12-31
SMT201900587T1 (en)	2019-11-13
JP6942853B2 (en)	2021-09-29
CN107667108B (en)	2020-05-12
BR112017025542A2 (en)	2018-08-07
ES2924698T3 (en)	2022-10-10
JP2018515581A (en)	2018-06-14
US20170305934A1 (en)	2017-10-26
US20180354974A1 (en)	2018-12-13
US12358931B2 (en)	2025-07-15
ME03610B (en)	2020-07-20
SA517390337B1 (en)	2021-03-31
PT3303348T (en)	2019-11-15
US20160347772A1 (en)	2016-12-01
EA032953B1 (en)	2019-08-30
JP6850922B2 (en)	2021-03-31
MX383074B (en)	2025-03-13
US10947254B2 (en)	2021-03-16
MX2020011774A (en)	2021-06-01
HUE046130T2 (en)	2020-02-28
AU2016267141A1 (en)	2017-11-16
CY1122279T1 (en)	2020-10-14
ZA201707326B (en)	2018-11-28
AU2016267141B2 (en)	2020-04-16
CO2017012267A2 (en)	2018-03-28
US20200040010A1 (en)	2020-02-06
EP3303348B1 (en)	2019-08-07
PL3303348T3 (en)	2020-02-28
IL272057B (en)	2020-09-30
TW202108593A (en)	2021-03-01
EP3303348A1 (en)	2018-04-11
JP2021098757A (en)	2021-07-01
CL2017002994A1 (en)	2018-03-09
IL255358A0 (en)	2017-12-31
AU2020202181A1 (en)	2020-04-16
AU2020202181B2 (en)	2021-07-01
PH12017502050A1 (en)	2018-04-23
HK1245771A1 (en)	2018-08-31
TWI704152B (en)	2020-09-11
WO2016191524A1 (en)	2016-12-01
PH12017502050B1 (en)	2018-04-23
KR20180011272A (en)	2018-01-31
US9725470B2 (en)	2017-08-08
CA2983453A1 (en)	2016-12-01
UA121138C2 (en)	2020-04-10
RS59522B1 (en)	2019-12-31
DK3303348T3 (en)	2019-11-11
IL276677B (en)	2021-05-31
IL276677A (en)	2020-09-30
CN107667108A (en)	2018-02-06
MX2017015211A (en)	2018-04-13
US10494382B2 (en)	2019-12-03
US10072026B2 (en)	2018-09-11
TWI746178B (en)	2021-11-11
CN111362975A (en)	2020-07-03
ES2753159T3 (en)	2020-04-07
CN111362975B (en)	2022-04-05
EA201792619A1 (en)	2018-04-30
IL272057A (en)	2020-02-27
TW201716416A (en)	2017-05-16
JP2021001196A (en)	2021-01-07

Publication	Publication Date	Title
IL276677B (en)	2021-05-31	Naphthyridine compounds as jak kinase inhibitors
HUS2400003I1 (en)	2024-03-28	Compounds useful as kinase inhibitors
IL268446A (en)	2019-09-26	5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
IL250709A0 (en)	2017-04-30	Aminopyrimidinyl compounds as jak inhibitors
ZA201700115B (en)	2020-05-27	Aminopyridazinone compounds as protein kinase inhibitors
ZA201807179B (en)	2019-08-28	Pyrimidine compounds as jak kinase inhibitors
IL255750A (en)	2018-01-31	Heterocyclic compounds as kinase inhibitors
PT3484875T (en)	2021-07-05	Pyrazolylaminobenzimidazole derivatives as jak inhibitors
GB201522245D0 (en)	2016-02-03	Compounds useful as kinase inhibitors
GB201613945D0 (en)	2016-09-28	Compounds useful as kinase inhibitors
GB201519382D0 (en)	2015-12-16	Kinase inhibitors
GB201519381D0 (en)	2015-12-16	Kinase inhibitors